Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AVC is a vaginal cream containing sulfanilamide, a sulfonamide antibiotic approved in 1965 for vaginal infections. It is applied topically to treat bacterial vaginitis and other vaginal infections caused by susceptible organisms. The drug works by inhibiting bacterial folate synthesis, thereby arresting bacterial growth.
As an aging legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely lean and focused on defensive strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
AAVCAGsCD59 for the Treatment of Wet AMD
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Worked on AVC at Pharmobedient? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on AVC offers limited career advancement given its legacy status, zero linked job openings, and approaching loss of exclusivity. This role is best suited for professionals seeking stability in a mature product rather than growth, launch, or innovation-focused opportunities.